How Big A Blow To Biogen Is NICE 'No' For Spinraza?
Executive Summary
The US biotech is aghast that the cost-effectiveness committee for England, Wales and Northern Ireland is minded to reject its effective but pricey SMA therapy which has gained blockbuster status already on strong sales elsewhere in Europe and the US.
You may also be interested in...
Stand-Off: Vertex Refuses NICE Data on CF Drug Symkevi, HTA Body Awaits Next Move
Vertex says it will not file data on its cystic fibrosis drug Symkevi (tezacaftor/ivacaftor) until the UK's NICE changes the way it assesses drugs.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.